1. Academic Validation
  2. High-throughput behavioral screen in C. elegans reveals Parkinson's disease drug candidates

High-throughput behavioral screen in C. elegans reveals Parkinson's disease drug candidates

  • Commun Biol. 2021 Feb 15;4(1):203. doi: 10.1038/s42003-021-01731-z.
Salman Sohrabi 1 Danielle E Mor 1 Rachel Kaletsky 1 William Keyes 1 Coleen T Murphy 2
Affiliations

Affiliations

  • 1 Department of Molecular Biology & Lewis Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, 08544, USA.
  • 2 Department of Molecular Biology & Lewis Sigler Institute for Integrative Genomics, Princeton University, Princeton, NJ, 08544, USA. ctmurphy@princeton.edu.
Abstract

We recently linked branched-chain amino acid transferase 1 (BCAT1) dysfunction with the movement disorder Parkinson's disease (PD), and found that RNAi-mediated knockdown of neuronal bcat-1 in C. elegans causes abnormal spasm-like 'curling' behavior with age. Here we report the development of a machine learning-based workflow and its application to the discovery of potentially new therapeutics for PD. In addition to simplifying quantification and maintaining a low data overhead, our simple segment-train-quantify platform enables fully automated scoring of image stills upon training of a convolutional neural network. We have trained a highly reliable neural network for the detection and classification of worm postures in order to carry out high-throughput curling analysis without the need for user intervention or post-inspection. In a proof-of-concept screen of 50 FDA-approved drugs, enasidenib, ethosuximide, metformin, and nitisinone were identified as candidates for potential late-in-life intervention in PD. These findings point to the utility of our high-throughput platform for automated scoring of worm postures and in particular, the discovery of potential candidate treatments for PD.

Figures
Products